Obesity drug discarded after being tied to patient deaths

Boston-based biotech company Zafgen has scrapped plans to bring binge-eating disorder treatment beloranib to market after two patients in clinical trials died after developing blood clots in their lungs.

The Food and Drug Administration placed the trials on hold, and Zafgen has decided it would be cost prohibitive to restart them, so it’s laying off a third of its staff and focusing on other research.

For more on what went wrong with a once-promising treatment, click on the link below: